These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3125056)

  • 21. [Prevention of rat galactose cataract with topical aldose reductase inhibitor, E-1008].
    Tasaka H; Akagi Y; Yoshikawa T; Ikebe H; Takahashi Y; Chamoto K; Miyamoto Y; Terubayashi H
    Nippon Ganka Gakkai Zasshi; 1987 Feb; 91(2):246-53. PubMed ID: 3111200
    [No Abstract]   [Full Text] [Related]  

  • 22. Spiro hydantoin aldose reductase inhibitors derived from 8-aza-4-chromanones.
    Sarges R; Goldstein SW; Welch WM; Swindell AC; Siegel TW; Beyer TA
    J Med Chem; 1990 Jul; 33(7):1859-65. PubMed ID: 2113948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphorus-31 NMR study of the effects of hydrogen peroxide on young and old rat lenses.
    Thomas DM; Mahendroo PP; Lou MF
    Exp Eye Res; 1990 Sep; 51(3):233-9. PubMed ID: 2401345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats.
    Kador PF; Lee JW; Fujisawa S; Blessing K; Lou MF
    J Ocul Pharmacol Ther; 2000 Apr; 16(2):149-60. PubMed ID: 10803425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishment of a naphthalene cataract model in vitro.
    Xu GT; Zigler JS; Lou MF
    Exp Eye Res; 1992 Jan; 54(1):73-81. PubMed ID: 1541343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies on the biochemical effects of the aldose reductase inhibitor 2,7-difluorospirofluorene-9,5'-imidazolidine-2',4'-dione (Al 1576, HOE 843). Detection of D-glucaric and D-glucuronic acid excretion by high resolution 1H and 13C NMR spectroscopy.
    Hoyle VR; Gilbert PJ; Troke JA; Vose CW; Nicholson JK
    Biochem Pharmacol; 1992 Jul; 44(2):231-41. PubMed ID: 1642638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of an aldose reductase inhibitor, 1-[(p-bromophenyl)-sulfonyl]hydantoin, on cataract formation and tissue polyol levels in galactosemic rats.
    Okuda J; Yashima K; Inagaki K; Miwa I
    Chem Pharm Bull (Tokyo); 1985 Jul; 33(7):2990-5. PubMed ID: 3936627
    [No Abstract]   [Full Text] [Related]  

  • 28. The prevention of biochemical changes in lens, retina, and nerve of galactosemic dogs by the aldose reductase inhibitor AL01576.
    Lou MF; Dickerson JE; Chandler ML; Brazzell RK; York BM
    J Ocul Pharmacol; 1989; 5(3):233-40. PubMed ID: 2516529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study of aldose reductase inhibition in intact lenses by 13C nuclear magnetic resonance spectroscopy.
    Williams WF; Odom JD
    Science; 1986 Jul; 233(4760):223-5. PubMed ID: 3088727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antioxidant status in an in vitro model for hyperglycemic lens cataract formation: effect of aldose reductase inhibitor statil.
    Hothersall JS; Taylaur CE; McLean P
    Biochem Med Metab Biol; 1988 Oct; 40(2):109-17. PubMed ID: 3142503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Raman spectroscopic study of the effect of aldose reductase inhibitor on experimental diabetic cataract.
    Nozawa H; Yaginuma T; Mizuno A
    Nippon Ganka Gakkai Zasshi; 1988 Jan; 92(1):194-201. PubMed ID: 3133929
    [No Abstract]   [Full Text] [Related]  

  • 32. Determination of AL01576 concentration in rat lenses and plasma by bioassay for aldose reductase activity measurements.
    Hockwin O; Müller P; Krolczyk J; McCue BA; Mayer PR
    Ophthalmic Res; 1989; 21(4):285-91. PubMed ID: 2511536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
    Peterson MJ; Sarges R; Aldinger CE; MacDonald DP
    Metabolism; 1979 Apr; 28(4 Suppl 1):456-61. PubMed ID: 122297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study.
    Datiles M; Fukui H; Kuwabara T; Kinoshita JH
    Invest Ophthalmol Vis Sci; 1982 Feb; 22(2):174-9. PubMed ID: 6799419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Organophosphate metabolic changes in the rat lens during the development of galactose-induced cataract.
    Sakagami K; Igarashi H; Tanaka K; Yoshida A
    Hokkaido Igaku Zasshi; 1999 Nov; 74(6):457-66. PubMed ID: 10642892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The possible mechanism of naphthalene cataract in rat and its prevention by an aldose reductase inhibitor (ALO1576).
    Xu GT; Zigler JS; Lou MF
    Exp Eye Res; 1992 Jan; 54(1):63-72. PubMed ID: 1541342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonosmotic diabetic cataracts.
    Malone JI; Lowitt S; Cook WR
    Pediatr Res; 1990 Mar; 27(3):293-6. PubMed ID: 2138728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nerve growth factor (NGF) and lenses: effects of NGF in an in vitro rat model of cataract.
    Ghinelli E; Aloe L; Cortes M; Micera A; Lambiase A; Bonini S
    Graefes Arch Clin Exp Ophthalmol; 2003 Oct; 241(10):845-51. PubMed ID: 13680251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of cataractogenesis on the CDP-choline pathway: changes in ATP concentration and phosphocholine synthesis during and after exposure of rat lenses to sugars in vitro and in vivo.
    Liu Y; Blum PS; Pabst DM; Chakrabarti I; Jernigan HM
    Ophthalmic Res; 2003; 35(4):185-91. PubMed ID: 12815193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of aldose reductase inhibitors by determination of IC50 with bovine and rat lens extracts.
    Müller P; Hockwin O; Ohrloff C
    Ophthalmic Res; 1985; 17(2):115-9. PubMed ID: 3920598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.